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Decoy receptors have ligand binding capacity but, in contrast to cognate receptors, do not initiate
typical downstream signaling cascades. In this issue of Developmental Cell, Klein and colleagues (2014)
demonstrate that CXCR7 acts as a decoy receptor for adrenomedullin, a peptide hormone with key roles
in cardiovascular development.Atypical, or ‘‘decoy,’’ chemokine recep-
tors comprise a class of 7-transmem-
brane-spanning (7TM) receptors that
bind to and regulate the bioavailability of
chemokines, an expansive family of fac-
tors that play myriad roles in develop-
ment, immunity, and inflammation (Nibbs
andGraham, 2013). In contrast to the abil-
ity of 7TM G protein-coupled receptors
(GPCRs) to activate signaling pathways
upon binding their cognate chemokines,
atypical chemokine receptors lack the ca-
pacity to initiate downstream signaling
following ligand binding. As a result, they
act as ‘‘sinks,’’ capturing chemokines
and restricting their access to cognate
receptors, thereby adding a layer of com-
plexity to the regulation of chemokine
signaling. In this issue of Developmental
Cell, Klein et al. (2014) show that the
decoy receptor CXCR7 attenuates adre-
nomedullin signaling during cardiovascu-
lar development.
CXCR7, also known as atypical chemo-
kine receptor 3 (ACKR3), is best charac-
terized as a receptor for SDF-1/CXCL12.
CXCR7 sequesters CXCL12, attenuating
the capacity of CXCL12 to signal through
its cognate receptor, CXCR4. Previous
work demonstrated that the majority of
Cxcr7/ mice die perinatally and exhibit
cardiac phenotypes, including cardio-
myocyte hyperplasia, ventricular septal
defects, and semilunar valve defects
(Gerrits et al., 2008; Sierro et al., 2007).
However, none of these phenotypes
could be ascribed simply to elevated
CXCL12 signaling through CXCR4, sug-
gesting additional functions of CXCR7.
Here, Klein et al. (2014) provide a novel
explanation for the cardiovascular pheno-
types of Cxcr7/ mice, demonstrating490 Developmental Cell 30, September 8, 201that CXCR7 also acts as a decoy receptor
for adrenomedullin. Moreover, they dem-
onstrate that Cxcr7/ mice exhibit strik-
ing defects in lymphatic vascular devel-
opment, a phenotype also attributed
to elevated adrenomedullin signaling
(Figure 1).
Adrenomedullin (AM) is a peptide hor-
mone, first identified as a potent vasodi-
lator (Kitamura et al., 1993), that activates
cognate receptors comprised of calci-
tonin receptor-like receptor (CLR) and re-
ceptor activity-modifying protein (RAMP)
components. Genetic disruption of AM
signaling results in embryonic lethality
due to key roles for this pathway in cardiac
and lymphatic vascular development
(Fritz-Six et al., 2008; Ichikawa-Shindo
et al., 2008). Similarities between the car-
diovascular defects of Cxcr7/ mice and
mice ectopically expressing AM (Wetzel-
Strong et al., 2014), coupledwith an earlier
observation that CXCR7 could bind AM
(Kapas and Clark, 1995), prompted Klein
and colleagues to determine whether
CXCR7 acts as a decoy receptor for AM
during cardiovascular development.
Klein and colleagues first established
that Cxcr7 expression is responsive to
AM in both cardiac tissue and isolated
lymphatic endothelial cells (LECs). They
next demonstrated that CXCR7 binds AM
and negatively regulates the level of ERK
phosphorylation induced by AM in vitro.
Importantly, elevated levels of phosphory-
lated ERK were observed in vivo, in the
lymphatic vasculature of Cxcr7/ mice.
The authors also made the intriguing
observation that CXCR7 levels in the
lymphatic vasculature, rather than being
uniform,appear tobedynamic, suggesting
that spatial and temporal regulation of4 ª2014 Elsevier Inc.Cxcr7 expression may determine which
cells are responsive to AM signals during
development.
The effects of Cxcr7 deletion on
lymphatic vascular development were
next assessed. Cxcr7/ embryos exhibi-
ted phenotypes indicative of enhanced
LEC proliferation, including enlarged jug-
ular lymph sacs and hyperplastic dermal
and cardiac lymphatic vessels. In vitro
studies revealed that Cxcr7 knockdown
in primary LECs promoted both prolif-
eration and migration in response to AM
treatment. Correspondingly, ectopic ex-
pression of Cxcr7 in HEK293T cells ex-
pressing the AM receptor components
CLR and RAMP2 blunted their migration
in response to AM. Together, these data
suggest that the lymphatic vascular phe-
notypes observed in Cxcr7/ embryos
are likely due to heightened sensitivity of
LECs to AM.
A second striking phenotype of
Cxcr7/mice was the presence of blood
in their jugular lymph sacs. This suggested
that the development of lymphovenous
valves, important for separating the blood
and lymphatic vascular compartments,
could be compromised in Cxcr7/ mu-
tants. The authors found, however, that
the morphology of these valves appeared
normal in Cxcr7/ embryos and pro-
posed that the blood-filled lymph sac
phenotype was more likely due to pre-
cocious development of the lymphatic
vasculature as a result of Cxcr7 inacti-
vation. A yet-to-be-answered question,
given that effective separation of the
blood and lymphatic vascular networks
requires both lymphovenous valves and
intact platelet activation pathways (Hess
et al., 2014), is whether potential defects
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Figure 1. CXCR7 Acts as a Decoy Receptor for Adrenomedullin during Cardiovascular Development
Binding of AM by CXCR7 in the lymphatic vasculature of wild-type mice effectively restricts the amount of AM available to bind cognate CLR/RAMP2 receptors
and initiate downstream signal transduction, an event that culminates in phosphorylation of ERK (pERK). In Cxcr7/ mice, more AM is available to bind CLR/
RAMP2 receptors, resulting in elevated downstream signaling that promotes lymphatic endothelial cell proliferation and migration, leading to lymphatic vessel
hyperplasia.
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Cxcr7/ mice may contribute to the
blood-filled lymphatic phenotype.
The authors then performed a key
experiment testing the consequences of
genetically titrating AM levels on the
phenotype of Cxcr7/ mice. They
crossed Cxcr7+/ mice with Cxcr7+/;
Adm+/ mice or Admhi/hi mice, a trans-
genic strain engineered to overexpress
AM (Wetzel-Strong et al., 2014). As hy-
pothesized, Cxcr7/;Adm+/ embryos
exhibited improved survival compared to
their Cxcr7/ counterparts, demon-
strating that reducing Adm dosage
rescued the cardiac and lymphatic vessel
hyperplasia phenotypes of Cxcr7/ em-
bryos. Consistently, artificial elevation of
AM levels in a Cxcr7-deficient back-
ground was not tolerated, as evidenced
by embryonic lethality of Cxcr7/;
Admhi/hi mice. These data provide
convincing evidence that CXCR7 plays a
crucial role in ‘‘setting’’ the appropriate
levels of AM signaling required for cardiac
and lymphatic vascular development
in vivo and demonstrate that dialing the
activity of this signaling axis either up ordown has profound consequences on
cardiovascular function.
This insightful study expands the cata-
log of roles played by the atypical chemo-
kine receptor CXCR7 and demonstrates
that CXCR7 regulates cardiovascular de-
velopment by acting as a decoy receptor
for AM. Moreover, this work raises the
intriguing possibility that temporal regu-
lation of CXCR7 levels, at least in the
lymphatic vasculature, may be important
for setting the threshold at which LECs
respond to this key prolymphangiogenic
stimulus. Understanding the signals that
control Cxcr7 expression spatially and
temporally, together with further elabora-
tion of the componentry important for
AM signaling in the cardiac and lymphatic
vascular compartments, will not only aid
our understanding of this key signaling
axis but also open new avenues for the
rational design of therapeutic agents for
the treatment of cardiovascular disease.REFERENCES
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